Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapies for Type 1 Diabetes
SAN DIEGO and SAN FRANCISCO, February 23, 2017 – ViaCyte, Inc., a privately-held regenerative medicine company, and Beyond Type 1, a not-for-profit advocacy and education group for those living with type 1 diabetes, today announced a grant from Beyond Type 1 to